miR-30b-3p Inhibits the Proliferation and Invasion of Lung Adenocarcinoma
by Targeting COX6B1
Background and objective Lung adenocarcinoma (LUAD) is the most common clinical histological subtype of lung cancer and microRNAs (miRNAs) are a type of small non-coding RNAs which play a central role in cells. miR-30b-3p plays a key effect in many types of carcinoma, but there is still very little research on how it works in lung adenocarcinoma. The role and mechanism of miR-30b-3p in the proliferation and invasion of LUAD were explored in this study, to provide new targets for inhibiting the proliferation and invasion of LUAD. Methods NCBI database was used to screen out miRNA with obvious differential expression, and th...
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research
Consideration on the Research and Development of New Drugs for Rare Tumors
In recent years, China ' s anti-tumor drugs has shown a continuous growth trend, and the activity of anti-tumor research and development in China accounts for a higher proportion in the world. However, further analysis of research and development hotspots show that the research and development of anti-tumor drugs is uneven among different tumor types. Due to the small number of the patients, it is difficult to conduct clinical trials, resulting in less drug development in the field of rare tumors. However, patients ' treatment needs will also bring potential opportunities for pharmaceutical companies. The development of ba...
Source: Chinese Journal of Lung Cancer - July 27, 2022 Category: Cancer & Oncology Source Type: research
Clinical Observation of Immunotherapy Efficacy and Adverse Effects
in Chinese Patients with Lung Squamous Cell Carcinoma
This study aimed to investigate the efficacy and toxicity of immunotherapy in patients with LUSC in Chinese population of real world. Methods A total of 185 LUSC patients underwent pathological diagnosis were involved from January 2018 to January 2022. Patients were divided into elderly group (age ≥70 years) and younger group (age0.05). Both combined group and immunology alone demonstrated prolonged mPFS in first-line compared with chemotherapy in elderly group. And combined group demonstrated significantly prolonged mPFS compared with chemotherapy in younger group (P (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Research Progress of Antitumor Pharmacovigilance
We described the difficulties in antitumor pharmacovigilance and current characteristics of pharmacovigilance in China, aiming to provide reference for the development of antitumor pharmacovigilance.
DOI: 10.3779/j.issn.1009-3419.2022.101.33 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Clinical Value of Autoantibody Prognostic Markers in Tumor Immune Checkpoint
Inhibitor Therapy
Serum autoantibody markers have the advantages of easy specimen acquisition, simple detection technology and dynamic real-time monitoring. With the wide application of immune checkpoint inhibitors in the treatment of malignant tumors, autoantibody markers in predicting tumor immune checkpoint inhibitors efficacy and forecasting irAEs (immune related adverse events) show good prediction of potential. This review mainly focused on the progress of autoantibody markers in the prediction of therapeutic effect and the monitoring of irAE in tumor immunotherapy.
DOI: 10.3779/j.issn.1009-3419.2022.101.28 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Progress of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer
Neoadjuvant immunotherapy, including neoadjuvant single- or dual-drug immunotherapy or combined immunotherapy with chemotherapy or radiotherapy, has witnessed a rapid development in non-small cell lung cancer. Clinical trials exhibited the encouraging pathological responses and certain clinical benefits in selected patients, with tolerable toxicity. Nivolumab with chemotherapy has been approved by Food and Drug Administration (FDA) as the first immunotherapy-based treatment for non-small cell lung cancer in the neoadjuvant treatment setting. There is the need for further evaluation of long-term efficacy, side effects or su...
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Advances in Diagnosis and Treatment of Leptomeningeal Metastasis of Lung Cancer
Leptomeningeal metastases (LM), a special type of metastasis in advanced lung cancer, is known for its severe clinical symptoms, rapid progression and poor prognosis. LM used to be featured with low clinical diagnosis rate, limited treatment options, poor treatment efficacy, and very short survival if treatment not given. Though cerebrospinal fluid (CSF) cytology remains to be the gold standard for the diagnosis of LM, the positive rate of the first CSF cytology even in patients with suggestive clinical symptoms and positive imaging generally does not exceed 50%, leading to a delay in the diagnosis and treatment of patient...
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Challenges of Investigator-initiated Clinical Trials to Support
the New Drug Development
A large number of investigator-initiated clinical trials (IIT) were conducted in China, some of them should play an important supporting role in new drug development. Due to the large number, small scale and uneven quality of IIT in China, especially a big gap between the IIT and industry-sponsored trials in terms of protocol design, quality management and ethical review, many IIT can ’t be used to support the new drug development. Therefore, it is necessary for regulatory authorities, sponsors, research institutions, ethics committees and researchers to improve their understanding of the role of IIT. In order to support...
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Discussion on the Focus of On-site Inspection of Clinical Trials of Lung Cancer
Targeted Therapy and Immunotherapy Drugs
As lung cancer targeted therapy and immunotherapy drugs are the current hot spot in the research and development area of new anti-tumor drugs, the amount of clinical trial in this area is increasing year by year. On the basis of combing the on-site inspections of drug registration clinical trials from 2019 to 2021, combined with the characteristics of lung cancer targeted therapy and immunotherapy drugs, this paper discusses the focus of on-site inspection of clinical trials of such drugs, and puts forward suggestions for the compliant implementation of lung cancer clinical trials.
DOI: 10.3779/j.issn.1009-3419.2022.10...
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
The Role and Function of Clinical Research Nurses in Anti-tumor Drug Clinical Trials for Lung Cancer Patients
Clinical trials of anti-tumor drugs is not only the important way to develop new drugs, but also the most advanced treatment methods for malignant tumors, bringing survival benefits to patients. There are a large number of new anti-tumor drug clinical trials for lung cancer patients, covering a wide variety of anti-tumor drugs, and with rapid progress and high efficiency of clinical transformation. These trials could not be carried out successfully without the joint efforts of the research team, in which the research nurses also played a role that should not be underestimated. Combined with the work content of clinical res...
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer
Patients with EGFR/MET Gene Abnormalities: A Single Center’s Experience
Conclusion Amivantamab was effective in Chinese NSCLC patients with EGFR exon 20 insertion and post-Osimertinib EGFR-mutant patients, similar to the results of clinical trials conducted in western countries. Amivantamab was well tolerated and emphases should be put on adverse events such as rash, paronychia, and infusion-related reactions.
DOI: 10.3779/j.issn.1009-3419.2022.102.26 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Application of MIDD in Clinical Research of Antitumor Drugs
The antitumor drug has become one of the focused areas in new drug research and development. Their clinical research generally consumes a long period of time, with high cost and high risk. Model-informed drug development (MIDD) integrates and quantitatively analyzes physiological, pharmacological, and disease progression information through modeling and simulation, which can reduce the cost of drug development and improve the efficiency of clinical research. In this essay, Osimertinib and Pembrolizumab are given as examples to illustrate the specific application of MIDD in different phases of clinical research, aiming to p...
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Opportunities and Challenges of RNA Interference Therapeutics in Oncology
As the discovery of RNA interference (RNAi) and the gradual conquering of a series of technical issues, a few of RNAi therapeutics have been approved in the non-tumor field abroad. With the advantages of high specificity, long duration of efficacy, and high success rate of development, RNAi therapeutics have become the emerging field globally. There are no RNAi therapeutics approved in oncology so far, and people are hoping a breakthrough in the field. In the present article, the characteristics and potential anti-tumor mechanism of RNAi therapeutics, difficulties in delivery system and progress in oncology are described, ...
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy
Proteolysis targeting chimeria (PROTAC) degrades target proteins by utilizing the ubiquitin-proteasome pathway, subverting the concept of traditional small molecule inhibitors. Among the common mutation targets of non-small cell lung cancer (NSCLC), PROTAC technology has successfully achieved the effective degradation of kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK ) and other proteins in preclinical studies. PROTAC drugs with their unique event-driven advantages, are expected to overcome acquired drug resistance caused by small molecule inhibit...
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Current Progress and Future Developments of Antibody Drug Conjugates
in Lung Cancer
Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system tumors, but also in lung cancer. The aim of this study was to provide informations for practice by summarizing the mechanism of action, clinical application and problems and challenges of ADCs.
DOI: 10.3779/j.issn.1009-3419.2022.102.22 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
